Genomics for the Advancement of Clinical Translation in Stroke

Rational Basis for Clinical Translation in Stroke Therapy

Volumn , Issue , 2014, Pages 123-136

  Brooks, Steven D ^a   Van Gilder, Reyna ^a,b   Frisbee, Jefferson C ^a   Barr, Taura L ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947074562     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16285-10     Document Type: Chapter

References (44)

1. Adams HP Jr, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34(4):1056-1083. doi: 10.1161/01.STR.0000064841.47697.22.
2. Agarwal N, Lippmann ES, Shusta EV. Identification and expression profiling of blood-brain barrier membrane proteins. J Neurochem 2010;112(3):625-635. doi: 10.1111/j.1471-4159.2009.06481.x.
3. Azab B, Chainani V, Shah N, McGinn JT. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: A 4-year follow-up study. Angiology 2013;64(6):456-465. doi: 10.1177/0003319712455216.
4. Baird AE. Blood genomics in human stroke. Stroke 2007;38(2 Suppl):694-698. doi: 10.1161/01.STR.0000250431.99687.7b.
5. Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A, Matarin M. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology 2010a;75(11):1009-1014. doi: 10.1212/WNL.0b013e3181f2b37f.
6. Barr TL, Latour LL, Lee KY et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010b;41(3):e123-e128. doi: 10.1161/STROKEAHA.109.570515.
7. Bevan S, Traylor M, Adib-Samii P et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke 2012;43(12):3161-3167. doi: 10.1161/STROKEAHA.112.665760.
8. Brooks SD, Spears C, Cummings C et al. Admission neutrophil-lymphocyte ratio predicts 90 day outcome after endovascular stroke therapy. J Neurointerv Surg 2013. doi: 10.1136/neurintsurg-2013-010780.
9. Buyukkaya E, Karakas MF, Karakas E, Akcay AB, Kurt M, Tanboga IH, Sen N. Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost 2012;20(2):159-163. doi: 10.1177/1076029612459675.
10. CDC.gov. Prevalence of Stroke-United States, 2006-2010. Morbid Mortal Wkly Rep 2012;61(20):379-382.
11. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke 1996;27(3):415-420.
12. Ertas G, Sonmez O, Turfan M et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J Neurol Sci 2013;324(1-2):49-52. doi: 10.1016/j.jns.2012.09.032.
13. Ghandour MS, Langley OK, Zhu XL, Waheed A, Sly WS. Carbonic anhydrase IV on brain capillary endothelial cells: A marker associated with the blood-brain barrier. Proc Natl Acad Sci USA 1992;89(15):6823-6827.
14. Goldstein LB, Jones MR, Matchar DB, Edwards LJ, Hoff J, Chilukuri V, Armstrong SB, Horner RD. Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke 2001;32(5):1091-1098.
15. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97(7):889-901.
16. Iadecola C, Anrather J. The immunology of stroke: From mechanisms to translation. Nat Med 2011a;17(7):796-808. doi: 10.1038/nm.2399.
17. Iadecola C, Anrather J. Stroke research at a crossroad: Asking the brain for directions. Nat Neurosci 2011b;14(11):1363-1368. doi: 10.1038/nn.2953.
18. Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44(3):870-947. doi: 10.1161/STR.0b013e318284056a.
19. Jickling GC, Sharp FR. Blood biomarkers of ischemic stroke. Neurotherapeutics 2011;8(3):349-360. doi: 10.1007/s13311-011-0050-4.
20. Jickling GC, Xu H, Stamova B et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol 2010;68(5):681-692. doi: 10.1002/ana.22187.
21. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: Clinical implications. Arch Neurol 2012;69(5):576-581. doi: 10.1001/archneurol.2011.3590.
22. Kidwell CS, Jahan R, Gornbein J et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368(10):914-923. doi: 10.1056/NEJMoa1212793.
23. Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol 2013;4:32. doi: 10.3389/fneur.2013.00032.
24. Lever NM, Nystrom KV, Schindler JL, Halliday J, Wira C 3rd, Funk M. Missed opportunities for recognition of ischemic stroke in the emergency department. J Emerg Nurs 2013;39(5):434-439. doi: 10.1016/j.jen.2012.02.011.
25. Liebeskind DS. Reperfusion for acute ischemic stroke: Arterial revascularization and collateral therapeutics. Curr Opin Neurol 2010;23(1):36-45. doi: 10.1097/WCO.0b013e328334da32.
26. Ludewig P, Sedlacik J, Gelderblom M, Bernreuther C, Korkusuz Y, Wagener C, Gerloff C, Fiehler J, Magnus T, Horst AK. CEACAM1 inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res 2013;113:1013-1022. doi: 10.1161/CIRCRESAHA.113.301207.
27. Mehta BP, Nogueira RG. Should clot composition affect choice of endovascular therapy? Neurology 2012;79(13 Suppl 1):S63-S67. doi: 10.1212/WNL.0b013e3182695859.
28. Moore DF, Li H, Jeffries N et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: A pilot investigation. Circulation 2005;111(2):212-221. doi: 10.1161/01.CIR.0000152105.79665.C6.
29. Moskowitz MA. Brain protection: Maybe yes, maybe no. Stroke 2010;41(10 Suppl):S85-S86. doi: 10.1161/STROKEAHA.110.598458.
30. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-477. doi: 10.1002/ana.20741.
31. Paciaroni M, Caso V, Agnelli G. The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol 2009;61(6):321-330. doi: 10.1159/000210544.
32. Palsson-McDermott EM, O’Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004;113(2):153-162. doi: 10.1111/j.1365-2567.2004.01976.x.
33. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Cho GY, Chae IH, Choi DJ. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111(5):636-642. doi: 10.1016/j.amjcard.2012.11.012.
34. Robeson RH, Siegel AM, Dunckley T. Genomic and proteomic biomarker discovery in neurological disease. Biomark Insights 2008;3:73-86.
35. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, Dallegri F, Bronte V, Ferrini S, Barbieri O. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 2011;89(5):721-727. doi: 10.1189/jlb.1109737.
36. Sharp FR, Xu H, Lit L et al. The future of genomic profiling of neurological diseases using blood. Arch Neurol 2006:63(11):1529-1536. doi: 10.1001/archneur.63.11.1529.
37. Smith CJ, Lawrence CB, Rodriguez-Grande B, Kovacs KJ, Pradillo JM, Denes A. The immune system in stroke: Clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol 2013;8(4):867-887. doi: 10.1007/s11481-013-9469-1.
38. Stamova B, Xu H, Jickling G et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010;41(10):2171-2177. doi: 10.1161/STROKEAHA.110.588335.
39. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102(6):653-657. doi: 10.1016/j.amjcard.2008.05.006.
40. Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR. Blood gene expression profiling of neurologic diseases: A pilot microarray study. Arch Neurol 2005;62(2):210-215. doi: 10.1001/archneur.62.2.210.
41. Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: A microarray study. J Cereb Blood Flow Metab 2006;26(8):1089-1102. doi: 10.1038/sj.jcbfm.9600264.
42. Thewissen M, Damoiseaux J, van de Gaar J, Tervaert JW. Neutrophils and T cells: Bidirectional effects and functional interferences. Mol Immunol 2011;48(15-16):2094-2101. doi: 10.1016/j.molimm.2011.07.006.
43. Tokgoz S, Kayrak M, Akpinar Z, Seyithanoglu A, Guney F, Yuruten B. Neutrophil lymphocyte ratio as a predictor of stroke. J Stroke Cerebrovasc Dis 2013;22(7):1169-1174. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.011.
44. VanGilder RL, Huber JD, Rosen CL, Barr TL. The transcriptome of cerebral ischemia. Brain Res Bull 2012;88(4):313-319. doi: 10.1016/j.brainresbull.2012.02.002.